KOD
Kodiak Sciences Inc.
Price Chart
Latest Quote
$34.09
-2.01 (-5.57%)
Current Price
| Previous Close | $36.10 |
| Open | $35.99 |
| Day High | $38.09 |
| Day Low | $33.58 |
| Volume | 1,021,084 |
Stock Information
| Shares Outstanding | 62.58M |
| Total Debt | $55.99M |
| Cash Equivalents | $169.53M |
| Net Income | $-230.66M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.13B |
| EPS (TTM) | $-4.17 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.13B |
| Income | $-230.66M |
| Book/sh | $1.81 |
| Cash/sh | $2.71 |
| Employees | 130 |
Financial Ratios
| Quick Ratio | 3.42 |
| Current Ratio | 3.54 |
| Debt/Eq | 49.95 |
Returns & Margins
| ROA | -49.05% |
| ROE | -208.80% |
Ownership
| Insider Ownership | 5.18% |
| Institutional Ownership | 99.62% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -10.94 |
| P/B | 18.86 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $62.67 |
Technical Indicators
| SMA20 | $34.24 |
| SMA50 | $38.42 |
| SMA200 | $26.90 |
| RSI | 49.80 |
| ATR | 2.8339 |
| Shares Float | 39.28M |
| Short Float | 26.16% |
| Short Ratio | 16.76 |
| Volatility | 2.21 |
| Rel Volume | 1.36 |
Performance History
| Week | -4.54% |
| Month | -5.31% |
| Quarter | +49.85% |
| 6 Months | +19.15% |
| YTD | +31.01% |
| Year | +844.32% |
| 3 Years | +316.24% |
| 5 Years | -58.96% |
| 10 Years | +235.53% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $34.09 | 1,021,084 |
| 2026-06-24 | $36.00 | 636,400 |
| 2026-06-23 | $37.05 | 586,400 |
| 2026-06-22 | $36.63 | 611,400 |
| 2026-06-18 | $36.14 | 1,205,900 |
| 2026-06-17 | $35.71 | 886,000 |
| 2026-06-16 | $32.94 | 412,900 |
| 2026-06-15 | $34.06 | 513,700 |
| 2026-06-12 | $34.06 | 630,100 |
| 2026-06-11 | $33.97 | 593,800 |
| 2026-06-10 | $31.41 | 697,500 |
| 2026-06-09 | $31.06 | 705,100 |
| 2026-06-08 | $29.61 | 822,300 |
| 2026-06-05 | $31.05 | 1,450,500 |
| 2026-06-04 | $34.16 | 749,600 |
| 2026-06-03 | $33.87 | 928,500 |
| 2026-06-02 | $33.22 | 836,900 |
| 2026-06-01 | $36.91 | 670,700 |
| 2026-05-29 | $36.71 | 596,600 |
| 2026-05-28 | $36.12 | 482,800 |
| 2026-05-27 | $35.09 | 504,300 |
| 2026-05-26 | $36.00 | 493,400 |
About Kodiak Sciences Inc.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
đ° Latest News
Kodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should Know
Motley Fool âĸ 2026-06-10T00:04:25Z
Kodiak Sciences (KOD) Is Down 15.4% After Strong Zenkuda GLOW2 Data And Accelerated Filing Plans
Simply Wall St. âĸ 2026-06-06T13:18:51Z
Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know
Zacks âĸ 2026-06-04T15:05:00Z
Boxer Capitalâs $18 Million Corvus Pharma Bet Signals Confidence in This Biotechâs Next Phase
Motley Fool âĸ 2026-05-17T20:46:06Z
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally
Motley Fool âĸ 2026-05-17T20:17:13Z
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
Motley Fool âĸ 2026-05-17T20:07:57Z
A Look At Kodiak Sciences (KOD) Valuation After Positive Phase 3 GLOW2 Results For Zenkuda
Simply Wall St. âĸ 2026-05-11T01:14:17Z
Zenkuda Phase 3 Win and Expanding Pipeline Might Change The Case For Investing In Kodiak Sciences (KOD)
Simply Wall St. âĸ 2026-05-10T19:09:07Z
Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus
Zacks âĸ 2026-05-08T16:39:00Z
Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?
Zacks âĸ 2026-04-30T15:30:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $0 | $0 | $13,000 | $18,000 |
| Total Expenses | $234,388,000 | $186,849,000 | $277,321,000 | $341,379,000 |
| Other Income Expense | $-96,000 | $-506,000 | $110,000 | $503,000 |
| Other Non Operating Income Expenses | $-96,000 | $-506,000 | $110,000 | $503,000 |
| Net Non Operating Interest Income Expense | $4,517,000 | $11,148,000 | $16,720,000 | $7,053,000 |
| Interest Expense Non Operating | $0 | $0 | $13,000 | $18,000 |
| Operating Expense | $234,388,000 | $186,849,000 | $277,321,000 | $341,379,000 |
| General And Administrative Expense | $52,015,000 | $60,754,000 | $71,023,000 | $73,788,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-229,967,000 | $-176,207,000 | $-260,491,000 | $-333,823,000 |
| Net Interest Income | $4,517,000 | $11,148,000 | $16,720,000 | $7,053,000 |
| Interest Income | $4,517,000 | $11,148,000 | $16,733,000 | $7,071,000 |
| Normalized Income | $-229,967,000 | $-176,207,000 | $-260,491,000 | $-333,823,000 |
| Net Income From Continuing And Discontinued Operation | $-229,967,000 | $-176,207,000 | $-260,491,000 | $-333,823,000 |
| Total Operating Income As Reported | $-234,388,000 | $-186,849,000 | $-277,321,000 | $-341,379,000 |
| Net Income Common Stockholders | $-229,967,000 | $-176,207,000 | $-260,491,000 | $-333,823,000 |
| Net Income | $-229,967,000 | $-176,207,000 | $-260,491,000 | $-333,823,000 |
| Net Income Including Noncontrolling Interests | $-229,967,000 | $-176,207,000 | $-260,491,000 | $-333,823,000 |
| Net Income Continuous Operations | $-229,967,000 | $-176,207,000 | $-260,491,000 | $-333,823,000 |
| Pretax Income | $-229,967,000 | $-176,207,000 | $-260,491,000 | $-333,823,000 |
| Interest Income Non Operating | $4,517,000 | $11,148,000 | $16,733,000 | $7,071,000 |
| Operating Income | $-234,388,000 | $-186,849,000 | $-277,321,000 | $-341,379,000 |
| Per Share | ||||
| Diluted EPS | $-4.32 | $-3.35 | $-4.97 | $-6.39 |
| Basic EPS | $-4.32 | $-3.35 | $-4.97 | $-6.39 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-203,647,000 | $-149,501,000 | $-234,531,000 | $-322,804,000 |
| Reconciled Depreciation | $26,320,000 | $26,706,000 | $25,947,000 | $11,001,000 |
| EBITDA (Bullshit earnings) | $-203,647,000 | $-149,501,000 | $-234,531,000 | $-322,804,000 |
| EBIT | $-229,967,000 | $-176,207,000 | $-260,478,000 | $-333,805,000 |
| Diluted Average Shares | $53,208,311 | $52,583,148 | $52,414,256 | $52,249,620 |
| Basic Average Shares | $53,208,311 | $52,583,148 | $52,414,256 | $52,249,620 |
| Diluted NI Availto Com Stockholders | $-229,967,000 | $-176,207,000 | $-260,491,000 | $-333,823,000 |
| Research And Development | $182,373,000 | $126,095,000 | $206,298,000 | $267,591,000 |
| Selling General And Administration | $52,015,000 | $60,754,000 | $71,023,000 | $73,788,000 |
| Other Gand A | $52,015,000 | $60,754,000 | $71,023,000 | $73,788,000 |
Fetched: 2026-06-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $157,383,000 | $150,288,000 | $265,781,000 | $436,167,000 |
| Total Assets | $351,533,000 | $335,578,000 | $479,372,000 | $666,628,000 |
| Total Non Current Assets | $136,717,000 | $163,642,000 | $190,063,000 | $180,623,000 |
| Other Non Current Assets | $14,853,000 | $14,912,000 | $15,040,000 | $64,870,000 |
| Current Assets | $214,816,000 | $171,936,000 | $289,309,000 | $486,005,000 |
| Other Current Assets | $4,954,000 | $3,862,000 | $3,802,000 | $7,072,000 |
| Cash Cash Equivalents And Short Term Investments | $209,862,000 | $168,074,000 | $285,507,000 | $478,933,000 |
| Cash And Cash Equivalents | $209,862,000 | $168,074,000 | $285,507,000 | $190,433,000 |
| Cash Equivalents | $207,585,000 | $166,464,000 | - | - |
| Cash Financial | $2,277,000 | $1,610,000 | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $59,180,000 | $70,345,000 | $81,632,000 | $87,733,000 |
| Long Term Debt And Capital Lease Obligation | $47,117,000 | $59,717,000 | $71,862,000 | $77,807,000 |
| Current Debt And Capital Lease Obligation | $12,063,000 | $10,628,000 | $9,770,000 | $9,926,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $194,150,000 | $185,290,000 | $213,591,000 | $230,461,000 |
| Total Non Current Liabilities Net Minority Interest | $148,617,000 | $159,717,000 | $171,862,000 | $177,965,000 |
| Other Non Current Liabilities | $101,500,000 | $100,000,000 | $100,000,000 | $100,158,000 |
| Current Liabilities | $45,533,000 | $25,573,000 | $41,729,000 | $52,496,000 |
| Payables And Accrued Expenses | $33,470,000 | $14,945,000 | $31,959,000 | $42,570,000 |
| Payables | $12,863,000 | $3,915,000 | $13,608,000 | $9,130,000 |
| Accounts Payable | $12,863,000 | $3,915,000 | $13,608,000 | $9,130,000 |
| Tradeand Other Payables Non Current | - | - | - | $0 |
| Other Current Liabilities | - | - | - | $-1,000 |
| Equity | ||||
| Common Stock Equity | $157,383,000 | $150,288,000 | $265,781,000 | $436,167,000 |
| Total Equity Gross Minority Interest | $157,383,000 | $150,288,000 | $265,781,000 | $436,167,000 |
| Stockholders Equity | $157,383,000 | $150,288,000 | $265,781,000 | $436,167,000 |
| Retained Earnings | $-1,558,705,000 | $-1,328,738,000 | $-1,152,531,000 | $-892,040,000 |
| Gains Losses Not Affecting Retained Earnings | - | - | $0 | $-1,307,000 |
| Other Equity Adjustments | - | - | - | $-1,307,000 |
| Other | ||||
| Ordinary Shares Number | $61,758,454 | $52,726,916 | $52,508,602 | $52,333,850 |
| Share Issued | $61,758,454 | $52,726,916 | $52,508,602 | $52,333,850 |
| Tangible Book Value | $157,383,000 | $150,288,000 | $265,781,000 | $436,167,000 |
| Invested Capital | $157,383,000 | $150,288,000 | $265,781,000 | $436,167,000 |
| Working Capital | $169,283,000 | $146,363,000 | $247,580,000 | $433,509,000 |
| Capital Lease Obligations | $59,180,000 | $70,345,000 | $81,632,000 | $87,733,000 |
| Total Capitalization | $157,383,000 | $150,288,000 | $265,781,000 | $436,167,000 |
| Additional Paid In Capital | $1,716,082,000 | $1,479,021,000 | $1,418,307,000 | $1,329,509,000 |
| Capital Stock | $6,000 | $5,000 | $5,000 | $5,000 |
| Common Stock | $6,000 | $5,000 | $5,000 | $5,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $47,117,000 | $59,717,000 | $71,862,000 | $77,807,000 |
| Current Capital Lease Obligation | $12,063,000 | $10,628,000 | $9,770,000 | $9,926,000 |
| Current Accrued Expenses | $20,607,000 | $11,030,000 | $18,351,000 | $33,440,000 |
| Net PPE | $121,864,000 | $148,730,000 | $175,023,000 | $115,753,000 |
| Accumulated Depreciation | $-59,472,000 | $-41,262,000 | $-22,552,000 | $-6,724,000 |
| Gross PPE | $181,336,000 | $189,992,000 | $197,575,000 | $122,477,000 |
| Leases | $96,514,000 | $96,534,000 | $96,534,000 | $43,483,000 |
| Construction In Progress | $5,157,000 | $4,204,000 | $4,371,000 | $4,519,000 |
| Other Properties | $36,606,000 | $46,508,000 | $54,541,000 | $59,369,000 |
| Machinery Furniture Equipment | $43,059,000 | $42,746,000 | $42,129,000 | $15,106,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | - | - | $0 | $288,500,000 |
| Dueto Related Parties Non Current | - | - | - | $99,996,000 |
Fetched: 2026-06-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-136,514,000 | $-117,719,000 | $-195,610,000 | $-253,822,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-136,008,000 | $-117,319,000 | $-154,183,000 | $-206,459,000 |
| Cash Flow From Continuing Operating Activities | $-136,008,000 | $-117,319,000 | $-154,183,000 | $-206,459,000 |
| Operating Gains Losses | - | - | $2,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-506,000 | $-400,000 | $-41,427,000 | $-47,363,000 |
| Investing Cash Flow | $-506,000 | $-755,000 | $249,226,000 | $-336,513,000 |
| Cash Flow From Continuing Investing Activities | $-506,000 | $-755,000 | $249,226,000 | $-336,513,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $172,960,000 | $0 | $0 | $0 |
| Financing Cash Flow | $178,302,000 | $501,000 | $31,000 | $1,895,000 |
| Cash Flow From Continuing Financing Activities | $178,302,000 | $501,000 | $31,000 | $1,895,000 |
| Net Common Stock Issuance | $172,960,000 | $0 | $0 | $0 |
| Common Stock Issuance | $172,960,000 | $0 | $0 | $0 |
| Net Other Financing Charges | - | - | $-211,000 | $-49,000 |
| Repurchase Of Capital Stock | - | - | - | $0 |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $0 | $13,000 | $18,000 |
| End Cash Position | $216,046,000 | $174,258,000 | $291,831,000 | $196,757,000 |
| Beginning Cash Position | $174,258,000 | $291,831,000 | $196,757,000 | $737,834,000 |
| Changes In Cash | $41,788,000 | $-117,573,000 | $95,074,000 | $-541,077,000 |
| Proceeds From Stock Option Exercised | $5,342,000 | $501,000 | $242,000 | $1,944,000 |
| Net Investment Purchase And Sale | $0 | $-355,000 | $290,653,000 | $-289,150,000 |
| Sale Of Investment | $0 | $0 | $340,000,000 | $138,616,000 |
| Purchase Of Investment | $0 | $-355,000 | $-49,347,000 | $-427,766,000 |
| Net PPE Purchase And Sale | $-506,000 | $-400,000 | $-41,427,000 | $-47,363,000 |
| Purchase Of PPE | $-506,000 | $-400,000 | $-41,427,000 | $-47,363,000 |
| Change In Working Capital | $6,846,000 | $-28,386,000 | $-7,355,000 | $11,961,000 |
| Change In Other Current Liabilities | $-11,165,000 | $-11,250,000 | $-8,922,000 | $7,907,000 |
| Change In Other Current Assets | $59,000 | $-12,000 | $426,000 | $7,384,000 |
| Change In Payables And Accrued Expense | $17,343,000 | $-17,064,000 | $-7,310,000 | $-586,000 |
| Change In Accrued Expense | $9,273,000 | $-7,371,000 | $-12,907,000 | $-2,246,000 |
| Change In Payable | $8,070,000 | $-9,693,000 | $5,597,000 | $1,660,000 |
| Change In Account Payable | $8,070,000 | $-9,693,000 | $5,597,000 | $1,660,000 |
| Change In Prepaid Assets | $609,000 | $-60,000 | $8,451,000 | $-2,744,000 |
| Other Non Cash Items | $20,000 | $355,000 | $-840,000 | $-563,000 |
| Stock Based Compensation | $58,863,000 | $60,213,000 | $88,556,000 | $106,033,000 |
| Asset Impairment Charge | $1,910,000 | $0 | $0 | - |
| Depreciation Amortization Depletion | $26,320,000 | $26,706,000 | $25,947,000 | $11,001,000 |
| Depreciation And Amortization | $26,320,000 | $26,706,000 | $25,947,000 | $11,001,000 |
| Depreciation | $26,320,000 | $26,706,000 | $25,947,000 | $11,001,000 |
| Net Income From Continuing Operations | $-229,967,000 | $-176,207,000 | $-260,491,000 | $-333,823,000 |
| Amortization Of Securities | - | $0 | $-846,000 | $-1,068,000 |
| Gain Loss On Sale Of PPE | - | $0 | $2,000 | $0 |
| Repayment Of Debt | - | - | - | $0 |
| Common Stock Payments | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
Fetched: 2026-06-24